Navigation Links
AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations
Date:2/16/2009

RESEARCH TRIANGLE PARK, N.C., Feb. 16 /PRNewswire/ -- AlphaVax announced today that it has hired Lynn Baird, PhD, as Vice President of Regulatory, Quality and Clinical Operations. In this capacity Lynn will provide leadership and strategic direction in the areas of regulatory and quality affairs and in clinical operations.

"Lynn's experience in directing successful clinical trials, developing regulatory strategy and gaining regulatory approval for clinical trials will complement our existing leadership team. We will look to Lynn to manage the regulatory affairs for in-house programs at AlphaVax as they move through clinical development, as well as coordinate and support regulatory activities of corporate partners involved with our alphavirus vector platform," said Andrew Graham, Vice President of Development at AlphaVax.

Most recently, Lynn was Sr. Vice President, Regulatory, Quality and Clinical Operations with CombinatoRx, Inc. in Cambridge, MA. Previous to that appointment, she held executive management positions for regulatory affairs and quality at Dyax, Curis and CytoTherapeutics. Lynn earned her Ph.D. in Microbiology and Immunology from Virginia Commonwealth University in Richmond, Virginia.

"We are truly delighted to attract someone of Lynn's caliber, capability and expertise. There is no doubt that she will play a significant role in our future growth and success as we advance multiple vaccine products through clinical development," said Jonathan Gelles, Chairman of AlphaVax's Board of Directors.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company's business strategy is to maximize the potential of this platform through a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance vaccines for influenza, cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP-compliant manufacturing facility is located in Lenoir, NC.


'/>"/>
SOURCE AlphaVax
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Health Announces New Name for Spinoff Company
2. ATS Medical Announces Fourth Quarter 2008 Earnings Release Date and Conference Call
3. URAC Announces Agenda for 2009 Best Practices in Health Care Consumer Empowerment and Protection Conference
4. Hill-Rom Announces Second Quarter 2009 Dividend
5. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
6. Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International
7. QLT announces that it is named as a defendant in an action
8. Biotel Announces Profitable Second Quarter Ended December 31, 2008
9. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
10. Investor Group Commends Jim Merselis for Joining Trinity Biotechs Board of Directors & Announces Conference Call Invitation
11. Cogdell Spencer Announces Dorr as President of the Southeast Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... the launch of Care Management Alerts and Dashboards, an innovative new service enabling ... Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data about ...
(Date:6/23/2017)... Beach, CA (PRWEB) , ... June 23, 2017 , ... ... has earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, ... in the top 1% of all charities reviewed by Charity Navigator and earns ANRF ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids ... risk of visual loss in these patients. , But how often do ophthalmologists and ... cessation to patients at risk of or with early symptoms of AMD? A ...
(Date:6/23/2017)... Newburgh, NY (PRWEB) , ... June 23, 2017 ... ... board certified plastic surgeon practicing in Newburgh, New York, has recently begun offering ... look. Committed to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein ...
(Date:6/23/2017)... , ... June 23, 2017 , ... Everybody has their ... while others prefer to read it, and some people don't like it at all. ... Here's what they found: , Erotic literature can give readers a taste of their ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)...  ivWatch LLC, a medical device company focused on ... is pleased to announce it was the Bronze Winner ... and Equipment at the 2017 Medical Design Excellence Awards ... The award was presented by Medical Device and Diagnostics ... New York during MD&M East, ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
(Date:6/8/2017)... Responding to Heath Ledger,s father,s recent call for ... Chris Cornell in May, the mental health watchdog group, ... psychiatric drug side effects search engine ... risks. The father of the late actor ... has called for tighter rules on prescription drugs. Speaking at ...
Breaking Medicine Technology: